Loading...
•
Jun 30, 2025
NeoGenomics Q2 2025 Earnings Report
NeoGenomics reported Q2 2025 results for the quarter ended June 30, 2025
Key Takeaways
NeoGenomics delivered 10% year-over-year revenue growth to $181,000,000 but widened net loss and saw profitability pressures due to impairments and higher operating costs while key clinical volumes and average revenue per test improved. Guidance for full-year 2025 was reduced.
Consolidated revenue increased to $181,000,000, up 10% versus prior year. :contentReference[oaicite:0]{index=0}
Net loss widened to $45,000,000 driven by impairment charges and higher operating expenses. :contentReference[oaicite:1]{index=1}
Average revenue per clinical test improved to $465. :contentReference[oaicite:2]{index=2}
Clinical volume grew, including strong NGS growth, but non-clinical revenue declined. :contentReference[oaicite:3]{index=3}
Forward Guidance
NeoGenomics reduced its full-year 2025 revenue and EBITDA guidance reflecting continued pharma revenue headwinds and delays in product launches, while emphasizing clinical growth and operational initiatives.
Positive Outlook
- Expect continued double-digit revenue growth driven by clinical testing demand. :contentReference[oaicite:4]{index=4}
- R&D enhancements and new product developments underway. :contentReference[oaicite:5]{index=5}
- Strengthening of sales team and partnerships to expand market reach. :contentReference[oaicite:6]{index=6}
- PanTracer Liquid Biopsy commercial launch anticipated to contribute revenue. :contentReference[oaicite:7]{index=7}
- Solid liquidity position with $164 million in cash and marketable securities. :contentReference[oaicite:8]{index=8}
Challenges Ahead
- Full-year revenue guidance lowered to $720–$726 million. :contentReference[oaicite:9]{index=9}
- Adjusted EBITDA guidance was reduced. :contentReference[oaicite:10]{index=10}
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...